Raphael Pharmaceutical Inc. Income (Loss) from Continuing Operations, Per Basic and Diluted Share
Raphael Pharmaceutical Inc. (RAPH) reported Income (Loss) from Continuing Operations, Per Basic and Diluted Share of -$0.15 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare · last filed 2022-03-30
- Raphael Pharmaceutical Inc. income (loss) from continuing operations, per basic and diluted share for fiscal 2021 was -$0.15.
- Raphael Pharmaceutical Inc. income (loss) from continuing operations, per basic and diluted share for fiscal 2020 was -$0.07.
| Period end | Income (Loss) from Continuing Operations, Per Basic and Diluted Share 12 month |
|---|---|
| 2021-12-31 | -$0.15 10-K · filed 2022-03-30 |
| 2020-12-31 | -$0.07 10-K · filed 2022-03-30 |